Leerink Partnrs Brokers Boost Earnings Estimates for REGN

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Leerink Partnrs upped their Q4 2024 earnings estimates for Regeneron Pharmaceuticals in a note issued to investors on Tuesday, January 28th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $9.82 per share for the quarter, up from their prior forecast of $8.81. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.73 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q1 2025 earnings at $6.80 EPS and FY2025 earnings at $33.55 EPS.

REGN has been the topic of a number of other research reports. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Bank of America reissued an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Trading Down 0.6 %

Shares of Regeneron Pharmaceuticals stock opened at $683.08 on Thursday. The stock has a market capitalization of $75.06 billion, a P/E ratio of 16.90, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $723.36 and a 200 day simple moving average of $928.61.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently bought and sold shares of the company. State Street Corp grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares during the period. International Assets Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after acquiring an additional 11,499 shares in the last quarter. Swiss National Bank raised its position in shares of Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock worth $338,079,000 after purchasing an additional 2,000 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after purchasing an additional 1,108 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.